Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies
PublisherSpringer International Publishing
MetadataShow full item record
AbstractNo specific antivirals are currently available for two emerging infectious diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature search was performed covering pathogenesis, clinical features and therapeutics, clinically developed drugs for repurposing and novel drug targets. This review presents current knowledge on the epidemiology, pathogenesis and clinical features of the SARS and MERS coronaviruses. The rationale for and outcomes with treatments used for SARS and MERS is discussed. The main focus of the review is on drug development and the potential that drugs approved for other indications provide for repurposing. The drugs we discuss belong to a wide range of different drug classes, such as cancer therapeutics, antipsychotics, and antimalarials. In addition to their activity against MERS and SARS coronaviruses, many of these approved drugs have broad-spectrum potential and have already been in clinical use for treating other viral infections. A wealth of knowledge is available for these drugs. However, the information in this review is not meant to guide clinical decisions, and any therapeutic described here should only be used in context of a clinical trial. Potential targets for novel antivirals and antibodies are discussed as well as lessons learned from treatment development for other RNA viruses. The article concludes with a discussion of the gaps in our knowledge and areas for future research on emerging coronaviruses.
SponsorsFunding This work was supported in part by the Division of Intramural Research and Division of Clinical Research, National Institute of Allergy and Infectious Diseases. This work was funded in part through Battelle Memorial Institute's prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272200700016I.
KeywordMiddle East Respiratory Syndrome Coronavirus
Severe Acute Respiratory Syndrome
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85034083736&doi=10.1007%2fs40265-017-0830-1&partnerID=40&md5=32b04da678f019a22f9c7f5dc98e5722; http://hdl.handle.net/10713/12398
- Broad-spectrum coronavirus antiviral drug discovery.
- Authors: Totura AL, Bavari S
- Issue date: 2019 Apr
- What are our pharmacotherapeutic options for MERS-CoV?
- Authors: Al-Tawfiq JA, Memish ZA
- Issue date: 2014 May
- Antivirals for Respiratory Viral Infections: Problems and Prospects.
- Authors: Liu Q, Zhou YH, Ye F, Yang ZQ
- Issue date: 2016 Aug
- Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
- Authors: Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA
- Issue date: 2013 Oct
- Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.
- Authors: Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB
- Issue date: 2020 Oct 14